Answers are grounded in this paper and cite their sources.
UCBT offers a cure for thalassemia and has advantages as a stem cell source for minorities where thalassemia is prevalent, but cell dose is critical for UCBT. Previously mortality risks outweigh benefits in using UCBT for thalassemia. With strategies that maximize cell dose – using non-red cell reduced but plasma depleted (PD) CB, no post-thaw wash (NW), and double cord transplantation (DCT) – promising results may be achieved with UCBT in young thalassemics. Between 7/2001 and 1/2006, 63 CB products were infused after Bu/Cy/ATG myeloablation in 51 pediatric thalassemia major patients (11 DCT & 1 re-transplant) at 14 transplant centers (TC) using 82% PD CB with 92% NW. Patient status: 20 Pesaro class 1, 11 class 2, 1 class 3, and 19 status unknown. Median age was 4.3 years (range 0.3–20 years) with a median weight of 17 kg (range 4–45 kg). The data was audited by TC, NMDP and on-site by CIBMTR with 97.3% accuracy. No significant adverse events were observed despite major ABO incompatibility in some cases and NW. Cumulative incidence estimates of neutrophil (ANC500), platelet 20K and platelet 50K (plt 20 & 50K) engraftment with donor chimerism were 86 ± 8%, 74 ± 9% and 74 ± 9%, and median times to ANC500, plt 20K and 50K engraftment were 17 days (range 11–32), 40 days (range 16–135) and 60 days (range 30–144) after transplantation respectively. 7 patients died including 2 deaths prior to day 20 and one due to traumatic head injury. 42 patients engrafted, 9 with autologous recovery, and 38 patients are alive with a mean and median follow up time of 537 and 296 days respectively (range 8–2,691 days) as of May 2007. Results appear to show improvement with TC experience TC (>5 cases of UCBT for thalassemia) and NW. Patients receiving PD versus red cell depletion (RCD) CB were compared by matched-pair analyses where patients were matched by TC experience, wash status, age, weight, TNC dose, and #HLA matches (Paired Prentice-Wilcoxon Test). The results (table) showed fewer autologous recovery (p = 0.04) and better thalassemia-free survival (DFS; p = 0.01) for PD compared to RCD patients. Overall survival (OS) and transplant-related mortality (TRM) also trended in favor of PD patients (both p = 0.08). To our knowledge, this is the largest multi-institutional UCBT series for thalassemia and demonstrate that at experienced TC, 93 ± 6% ANC engraftment and 88 ± 8% 1-year DFS are attainable, when cell dose is optimized with PD CBU, no post-thaw wash and DBT when necessary.Tabled 1ANC500Plt 50 KAutologous RecoveryTRMOSDFSP-valueNSNS0.040.080.080.01In favor ofPDPDPDPDNS = Not Significant. Open table in a new tab NS = Not Significant.
No takes yet. Share an insight, caveat, or question.
Jaing et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: